MedTrace Logo

Hyperpolarized Imaging in Diagnosing Participants With Glioma

NCT03739411 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-03-27

No results posted yet for this study

Summary

This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.

Conditions

Interventions

RADIATION

Hyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

RADIATION

Radiation Therapy

Undergo radiation therapy for cancer outside of this study.

DRUG

Chemotherapy

Undergo chemotherapy for cancer outside of this study.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Susan Chang

    lead OTHER

Principal Investigators

  • Susan Chang, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2028-06-01
Completion
2028-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739411 on ClinicalTrials.gov